German CDMO Adragos acquires major Sanofi sterile injectables plant near Paris

FRANCE—German contract development and manufacturing organization Adragos has purchased a large-scale sterile injectables facility from Sanofi located in Maisons-Alfort, just outside Paris.

The acquisition price remains undisclosed, but the deal represents a significant milestone for the growing CDMO.

The Maisons-Alfort plant, which previously operated under Sanofi’s ownership, specializes in fill-finish manufacturing at commercial scale.

The facility produces both liquid and lyophilized vials for injectable medications, handling the critical final stages of pharmaceutical production where drugs are filled into their final containers.

When combined with Adragos’ existing operations in France and Switzerland, the acquisition positions the company among Europe’s leading sterile injectables manufacturers.

The strategic purchase reflects Adragos’ broader expansion strategy across the continent.

Preserving workforce and operations

Adragos plans to retain the existing workforce at Maisons-Alfort, emphasizing that maintaining continuity of service remains a top priority.

The company views the integration of talent as a critical advantage for the site’s future development and performance.

“Maisons-Alfort is a landmark acquisition for Adragos and a defining step in our growth journey,” said Andreas Raabe, M.D., founder and CEO of Adragos, in a statement.

He outlined plans to invest in the facility and develop it into a premier fill-finish platform capable of serving major pharmaceutical clients.

Building on existing partnership

This latest transaction continues a partnership between Adragos and Sanofi that dates back to 2023.

In that earlier deal, Adragos acquired a pharmaceutical manufacturing facility in Kawagoe, Japan, near Tokyo.

The Japanese plant, operational for more than 50 years, produces oral solid medications and sterile liquid pharmaceuticals.

Beyond the asset purchase in Japan, Adragos and Sanofi signed a separate long-term supply agreement lasting five years.

Under this arrangement, Adragos manufactures pharmaceutical products for Sanofi in Japan, serving as the French pharmaceutical giant’s manufacturing partner in the region.

Strategic implications

The consecutive acquisitions demonstrate Adragos’ aggressive expansion in the contract manufacturing sector.

By securing production facilities across Europe and Asia, the CDMO strengthens its ability to serve global pharmaceutical companies seeking manufacturing partners with geographic flexibility and specialized capabilities in sterile injectable production.

The Maisons-Alfort facility’s proximity to major European markets, combined with its advanced manufacturing capabilities, makes it a valuable addition to Adragos’ portfolio.

The deal underscores growing consolidation in the CDMO industry, where manufacturers increasingly acquire specialized production assets to meet rising demand for outsourced pharmaceutical manufacturing services.